The collaboration is the latest in a series of partnerships for diabetes care announced by the medical device maker.
The medical device maker Medtronic has added the technology company Qualcomm to its list of partners for creating new tools to manage diabetes.
On Wednesday, Medtronic announced it had formed a collaboration with Qualcomm Life, a subsidiary, to develop “future generation” continuous glucose monitoring (CGM) systems, specifically for those with type 2 diabetes (T2D).
While CGM technology has become standard of care in type 1 diabetes (T1D), it is less common for those with T2D. Increasingly, however, those with advanced cases are treated with intensive regimens, including insulin, that resemble the care for persons with T1D.
Earlier this spring, Medtronic announced results from clinical trials that showed patients with T2D who switched to its MiniMed insulin pump had superior glycemic control over a 6-month period than those who used injections for insulin therapy. According to the American Diabetes Association, about 29 million people in the United States have diabetes, and all but 1.25 million have T2D.
In a statement, Medtronic’s Laura Stoltenberg, vice president and general manager for Non-Intensive Diabetes Therapies, said the company sees CGM as an “increasingly used diagnostic tool that empowers physicians and patients with meaningful glucose data to tackle glucose control.” Qualcomm Life’s leadership in wireless technologies, she said, will allow Medtronic to develop affordable systems for glucose monitoring by the T2D population.
“Qualcomm Life’s connected health expertise along with our enabling 2net Connectivity Platform and 2net Design capabilities fit naturally with Medtronic’s diabetes leadership in brining future generation CGM systems to the market,” Rick Valencia, president and general manager of Qualcomm Life, Inc., said in a statement.
A CGM system for T2D patients that was affordable and scalable would allow collection of blood glucose data without relying on patients to collect the data daily themselves. This could be valuable for physicians and health systems as diabetes outcomes increasingly become a critical element of reimbursement models as the nation moves toward value-based care.
Medtronic’s collaboration with Qualcomm is the latest in a series of partnerships, in areas of technology, therapy, and with payers. It has previously announced relationships with the diabetes data firm Glooko, insulin infusion set maker Becton, Dickinson & Co., and the insulin maker, Sanofi.
Its payer relationship with UnitedHealthcare, however, drew criticism from leaders in the T1D advocacy community when the insurer announced that it would begin transitioning most adult patients who use insulin pumps to Medtronic products starting July 1, 2016.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More